ONLINE MUTATION REPORT

A protein truncating BRCA1 allele with a low penetrance of breast cancer

B Gorski¹, J Menkiszak¹, J Gronwald¹, J Lubinski¹, S A Narod²

¹ Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland
² Centre for Research in Women’s Health, Toronto, ON, Canada

Correspondence to:
Correspondence to:
Dr S A Narod
Centre for Research in Women’s Health, 790 Bay Street, Toronto, Ontario, Canada M5G 1N8; steven.narod@sw.ca

Received 11 February 2004
Revised version received 19 July 2004

Accepted 20 July 2004

Keywords: BRCA1; breast cancer; penetrance

The first 150 words of the full text of this article appear below.

In the 10 years since the identification of the BRCA1 gene, many cancer families have been tested throughout the world, and there is ongoing interest in estimating the cancer risks for women with mutations in this gene. There is some evidence that families with mutations in the central part of BRCA1 (nucleotides 2401 to 4190) have a higher than expected ratio of ovarian to breast cancers, due to a lower than average risk of breast cancer.¹ The absolute and relative risks of breast and ovarian cancers associated with different mutations have been difficult to quantify, in part because of the large number of different mutations in the gene, the rarity of mutations in the general population, and the expense of testing. The majority of established BRCA1 mutations are protein truncating, although a number of deleterious missense mutations have also been identified.²

Poland is ideally suited to the study of the . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Risch, H. A., McLaughlin, J. R., Cole, D. E. C., Rosen, B., Bradley, L., Fan, I., Tang, J., Li, S., Zhang, S., Shaw, P. A., Narod, S. A. (2006). Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada. JNCI J Natl Cancer Inst 98: 1694-1706 [Abstract] [Full Text]  
• Gronwald, J, Huzarski, T, Byrski, B, Medrek, K, Menkiszak, J, Monteiro, A N, Sun, P, Lubinski, J, Narod, S A (2006). Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J. Med. Genet. 43: 424-428 [Abstract] [Full Text]